Clinical trial · Interventional
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to test \[90\]Y-ibritumomab tiuxetan, a radioactive antibody, in patients with stage III or IV follicular lymphoma whose disease is in partial or complete remission after first line chemotherapy. The radioactive antibody will be compared with no further treatment to see which is better in the long term after standard lymphoma treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no treatment | Other | — | UNRESOLVED |
| Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128) | Biological | Ibritumomab Tiuxetan | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm 1
- interventionNames
- Biological: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)
- type
- OTHER
- label
- Arm 2
- interventionNames
- Other: no treatment
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- End of study
Secondary outcomes (8)
- measure
- Clinical and molecular response rates
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Non Hodgkin Lymphoma stage III or IV at timepoint of diagnosis * Patients who have achieved a remission after first line chemotherapy * No less than 6 weeks and no more than 12 weeks since last dose of chemotherapy * older than 18 years * written informed consent Exclusion Criteria: * Any other anticancer treatment for NHL except the preceding first line chemotherapy * Prior radiation therapy * Patients who have not recovered from the toxic effects of the first line chemotherapy * Any other cancer or history of cancer less than 10 years ago * Patients with known HIV positivity * patients with pleural effusion or ascites * female patients who are pregnant or breast feeding (women of childbearing potential must have a negative serum pregnancy test at study entry) * Adults not employing an effective method of birth control during study treatment and 12 months thereafter * Patients unable or unwilling to comply with protocol
References
Publications (0)
Data not yet available